Fusion Pharmaceuticals, Inc. (FUSN)
Stock Price:
$12.40 USD
-0.18 (-1.43%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
516.63M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
41.66M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$12.40 |
| Previous Close |
$12.58 |
| Change ($) |
-0.18 |
| Change (%) |
-1.43% |
| Day's Open |
12.62 |
| Day's Range |
12.40 - 12.74 |
| Day's Volume |
17,606 |
| 52-Week Range |
12.19 - 19.00 |
More Stats
| Market Cap |
516.63M |
| Enterprise Value |
195.96M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
41.66M |
| Float |
16.69M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.64 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
320.67M |
| Net Cash / Share |
7.70 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$24.33*
(96.21% upside)
Low
23.0
Current: $12.40
High
25.0
Target: 24.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -18.22 | -10.10 | -6.99 |
| Net Income | -16.19 | -11.65 | -6.26 |
| Shares Outstanding | 1.92 | 1.87 | 1.87 |
| Earnings Per Share | -8.45 | -6.22 | -3.34 |
| Operating Cash Flow | -13.69 | -9.87 | -6.13 |
| Capital Expenditures | -0.46 | -1.12 | -0.10 |
| Free Cash Flow | -14.15 | -10.99 | -6.22 |
| Cash & Equivalents | 67.12 | 29.08 | 0.00 |
| Net Cash / Debt | 67.12 | 29.08 | 0.00 |
| Assets | 69.40 | 31.39 | - |
| Liabilities | 10.34 | 1.77 | - |
| Book Value | -33.49 | -17.92 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Fusion Pharmaceuticals, Inc. |
| Country |
Canada |
| Employees |
41 |
| CEO |
John Valliant |
Stock Information
| Ticker Symbol |
FUSN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FUSN |
| IPO Date |
June 26, 2020 |
Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada. Address: